| Title |
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
|
|---|---|
| Published in |
Clinical Sarcoma Research, June 2016
|
| DOI | 10.1186/s13569-016-0049-z |
| Pubmed ID | |
| Authors |
Kieuhoa T. Vo, Katherine K. Matthay, Steven G. DuBois |
| Abstract |
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients with these tumors. In the current review, the authors summarize the available evidence and possible mechanisms supporting this approach. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 23% |
| Researcher | 3 | 14% |
| Student > Master | 3 | 14% |
| Other | 2 | 9% |
| Student > Bachelor | 2 | 9% |
| Other | 3 | 14% |
| Unknown | 4 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 32% |
| Biochemistry, Genetics and Molecular Biology | 3 | 14% |
| Agricultural and Biological Sciences | 3 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
| Computer Science | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 4 | 18% |